Genomics

AI genomics firm partners with two major US health systems, aiming to accelerate cancer and rare disease diagnostics for 60,000 patients annually.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

Waters finalized its $18.8B merger with BD's units, doubling its size. But investor concerns over near-term performance sent shares tumbling.

Bionano's 2026 virtual event will showcase how Optical Genome Mapping is revolutionizing cancer and genetic disease research and paving a path to clinical use.

Early trial data for ABX1100 reveals a novel approach to reducing muscle damage in Pompe disease, offering hope for less burdensome treatment.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

A new initiative unites top scientists to study 'SuperAgers' and resilient brains, aiming to unlock the secrets of healthy aging and prevent Alzheimer's.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

A new partnership will integrate data from millions in India and the UAE, aiming to fix research bias and build more equitable AI-driven medicine.

Life sciences giant QIAGEN defies economic headwinds with strong 2025 results, signaling aggressive growth in single-cell analysis and bioinformatics.

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

JScreen, Manischewitz, and advocate Gila Pfeffer offer low-cost cancer and carrier genetic tests in NYC, transforming community health access.

After selling its proteomics arm to Illumina for $350M+, Standard BioTools is flush with cash but faces a pivotal moment to fix its core business.

Veteran leader Emma Rooth takes charge at PCCA UK, bringing a track record of transformation to the booming personalized medicine market.

Neurocrine Biosciences begins a Phase 2 trial for a new tardive dyskinesia drug, aiming to build on its market dominance and offer new hope for patients.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.

A bipartisan House bill aims to standardize Medicaid coverage for genetic sequencing, offering hope to families facing long waits for a diagnosis.

Equinox's new EQX ARC program partners with Oura and Function to offer hyper-personalized, data-driven training for women across all life stages.

Jennifer Erickson, a mentee of the retiring CEO, returns to lead Arizona's top lab, signaling a new era of innovation amid industry-wide shifts.